Sycomore Asset Management Purchases Shares of 101,488 Qiagen (NYSE:QGEN)

Sycomore Asset Management acquired a new position in Qiagen (NYSE:QGEN) during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 101,488 shares of the company’s stock, valued at approximately $4,425,000.

A number of other hedge funds and other institutional investors also recently modified their holdings of QGEN. Vanguard Group Inc. boosted its holdings in Qiagen by 1.0% during the fourth quarter. Vanguard Group Inc. now owns 8,815,467 shares of the company’s stock worth $382,856,000 after buying an additional 83,371 shares in the last quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main boosted its stake in shares of Qiagen by 0.8% during the 4th quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 3,481,873 shares of the company’s stock worth $151,526,000 after acquiring an additional 26,078 shares in the last quarter. Optiver Holding B.V. grew its holdings in shares of Qiagen by 1,211.4% in the 4th quarter. Optiver Holding B.V. now owns 47,212 shares of the company’s stock worth $2,050,000 after acquiring an additional 43,612 shares during the last quarter. Sei Investments Co. raised its position in shares of Qiagen by 49.0% during the fourth quarter. Sei Investments Co. now owns 1,196,476 shares of the company’s stock worth $51,963,000 after purchasing an additional 393,553 shares during the period. Finally, US Bancorp DE raised its position in shares of Qiagen by 124.4% during the first quarter. US Bancorp DE now owns 75,529 shares of the company’s stock worth $3,247,000 after purchasing an additional 41,868 shares during the period. Institutional investors own 70.00% of the company’s stock.

Qiagen Stock Performance

Shares of NYSE QGEN opened at $45.56 on Tuesday. Qiagen has a 12 month low of $34.74 and a 12 month high of $47.44. The company has a market cap of $10.40 billion, a P/E ratio of 30.55, a P/E/G ratio of 3.20 and a beta of 0.39. The business’s 50 day moving average is $45.26 and its two-hundred day moving average is $43.49. The company has a quick ratio of 1.46, a current ratio of 1.77 and a debt-to-equity ratio of 0.27.

Qiagen (NYSE:QGEN) last posted its quarterly earnings results on Wednesday, July 31st. The company reported $0.55 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.52 by $0.03. The company had revenue of $496.00 million for the quarter, compared to analyst estimates of $495.45 million. Qiagen had a net margin of 3.75% and a return on equity of 12.92%. The business’s quarterly revenue was down .2% on a year-over-year basis. During the same period last year, the business posted $0.53 EPS. On average, equities analysts expect that Qiagen will post 2.15 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on QGEN shares. JPMorgan Chase & Co. lifted their price target on Qiagen from $52.00 to $54.00 and gave the stock an “overweight” rating in a research note on Tuesday, June 18th. Wolfe Research raised shares of Qiagen from a “peer perform” rating to an “outperform” rating and set a $50.00 target price on the stock in a research report on Thursday, June 27th. Finally, Robert W. Baird raised their price objective on shares of Qiagen from $49.00 to $52.00 and gave the stock an “outperform” rating in a research note on Friday, August 2nd. Three analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat.com, Qiagen has a consensus rating of “Moderate Buy” and a consensus target price of $50.25.

Qiagen Profile

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.